Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Awad, Tahany ^a   Thorlund, Kristian ^a   Hauser, Goran ^b   Mabrouk, Mahasen ^c   Stimac, Davor ^b   Gluud, Christian ^a  

^a University of Copenhagen   (Denmark)

^b KBC RIJEKA   (Croatia)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; DEATH; EMBASE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HEMORRHAGE; MEDLINE; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SCISEARCH; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

EID: 70249119242     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005642.pub2     Document Type: Review

References (52)

1. Awad T, Thorlund K, Hauser G, Stimac D, Gluud C. Pegylated interferon alpha 2a for chronic hepatitis C. Cochrane Database of Systematic Reviews (submitted for publication).
2. Awad T, Thorlund K, Hauser G, Stimac D, Gluud C. Pegylated interferon alpha 2b for chronic hepatitis C. Cochrane Database of Systematic Reviews (submitted for publication).
3. Awad T, Thorlund K, Hauser G, Stimac D, Gluud C. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C: a network meta-analysis. Cochrane Database of Systematic Reviews (submitted for publication).
4. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, et al.Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis. Bioconjugate Chemistry 2001;12(2): 195-202. (Pubitemid 32235471)
5. Benvegnu L, Alberti A. Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus-related cirrhosis. Antiviral Research 2001;52:199-207. (Pubitemid 32973695)
6. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine April 2006;26(1):53-77.
7. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. CochraneDatabase of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005445]
8. Brok J, Thorlund K, Gluud C,Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008; 61(8):763-769
9. Bucher HC, Guyatt G, Griffith LE,Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50:683-691 (Pubitemid 27341818)
10. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al.Treatment of chronic hepatitis C: A systematic review. Hepatology 2002;36(S1):135-144 (Pubitemid 35253474)
11. Chou R, Carson S, Chan BKS. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Journal of Viral Hepatitis 2008 [Epub ahead of print]. [DOI: 10.1111/j.1365-2893.2008.00984.x]
12. Davis GL. Hepatitis C virus genotypes and quasispecies. American Journal of Medicine 1999;107(6B):21-6S.
13. Deeks JJ, Bradburn MJ, Bilker W, Localio R, Berlin J. Much ado about nothing: statistical methods for meta-analysis with rare events [abstract]. In: 6th International Cochrane Colloquium. Systematic reviews: evidence for action. 1998:50.
14. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-350
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-188
16. EggerM, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-634 (Pubitemid 27387172)
17. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology 2002;97(11):288-295
18. Foster GR. Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology & Therapeutics 2004;20(8):825-830
19. FriedMW, ShiffmanML, Reddy KR, Smith C,MarinosG,Goncales FLJr, et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002;347: 975-982
20. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al.Pegylated interferon-[alpha]2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics 2000;68(5):556-567 (Pubitemid 30953875)
21. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration: Cochrane Review Groups (CRGs). John Wiley & Sons, Ltd, 2008, issue 3.
22. Hadziyannis SJ, SetteH,Morgan TR, BalanV,DiagoM,Marcellin P, et al.Peginterferon alfa-2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140:346-355
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Statistics in Medicine 2002;21(11):1539-1558
24. Higgins JPT,Green S.CochraneHandbook for SystematicReviews of Interventions Version 5.0.0. The Cochran Collaboration, 2008. Available from www.cochrane-handbook.org, [updated February 2008].
25. HodgsonHJF. Viral hepatitis - clinical aspects. In: David A.Warrell, Timothy M. Cox, John D. Firth, Edward J. Benz Jr editor(s). Oxford Textbook of Medicine. 4th Edition. Oxford/ New York: Oxford University Press, 2003.
26. International conference on harmonisation expert working group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR & ICH Guidelines. Code of federal regulations and ICH guidelines. Vol. 1, 1400 North Providence Road, Media, PA 19063-2043 USA: Barnett International/PAREXEL, Clinical Training Group, 1997.
27. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology & Therapeutics 2004;20(9):931-938 (Pubitemid 39593273)
28. Kjaergard LL, Villumsen J,Gluud C. Reportedmethodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-989
29. LuG,Ades AE.Combination of direct and indirect evidence inmixed treatment comparisons. Statistics in Medicine 2004;23:3105-3124
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 2001;358(9286):958-965 (Pubitemid 32913521)
31. Moher D, PhamB, Jones A,Cook DJ, JadadAR,MoherM, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-613 (Pubitemid 28380142)
32. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al.Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000370]
33. UnitedNetwork for Organ Sharing. 2005 OPTN/SRTR AnnualReport (Chapter VI ; Liver and Intestine Transplantation in the United States, 1995-2004). http://www.optn.org (accessed April 13, 2008).
34. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32(3):654-659 (Pubitemid 30676929)
35. Pawlotsky JM.Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(5):S65-S73.
36. Penin F,Dubuisson J, Rey FA,Moradpour D, Pawlotsky J. Structural biology of hepatitis C virus. Hepatology 2004; Vol.39, issue 1: 5-19. [DOI: 10.1002/hep.20032]
37. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, ReindollarR, et a. Efficacy and safety of pegylated (40-kd) interferonalpha- 2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33(2):433-438 (Pubitemid 32119033)
38. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology 2001;313:451-464 (Pubitemid 33052278)
39. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003; 19(4):591-603. (Pubitemid 38405633)
40. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes.. Statistics in Medicine 2008;27:746-763 (Pubitemid 351278817)
41. Schulz KF,Chalmers I,Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-412
42. Seeff LB, Hoofnagle JH. National institutes of health consensus development conference: Management of hepatitis C: 2002. Hepatology 2002; Vol.36, issue S1:S1-S2. [DOI: 10.1002/hep.1840360702]
43. Shepherd J, Brodin H, Kan FT, Cave CB, Waugh NR, Price A, et al.Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. International Journal of Technology Assessment in Health Care 2005;21(01):47-54. (Pubitemid 40229368)
44. Siebert U, Sroczynski G, German Hepatitis C Model GEHMO Group, HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German FederalMinistry of Health and Social Security. International Journal of Technology Assessment in Health Care 2005;21(01): 55-65. (Pubitemid 40229369)
45. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2007;25(10):1153-1162 (Pubitemid 46650293)
46. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. European Journal of Gastroenterology & Hepatology 1996; 8:324-328 (Pubitemid 26171215)
47. StraderDB,WrightT, Thomas LD, Seeff LB. AASLDpractice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147-1171
48. van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al.Virus Taxonomy: The Classification and Nomenclature of Viruses. The Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000:599-621.
49. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative metaanalysis. Journal of Clinical Epidemiology 2008;61(1):64-75. (Pubitemid 350245732)
50. WHO.Hepatitis C. www.who.int/mediacentre/factsheets/fs164/en/ (accessed April 7, 2008).
51. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-605
52. Zaman A, Fennerty MB, Keeffe EB. Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2003;18(7):661-670 (Pubitemid 37271831)